OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment
OptimizeRx (Nasdaq: OPRX) has announced plans to appoint a new independent director to its Board during the second half of 2025, continuing its board refreshment initiative. This appointment will mark the third new director since 2020, following Catherine Klema (2024) and Gregory D. Wasson (2020) additions.
The company, which specializes in healthcare technology solutions connecting life sciences companies with healthcare professionals and patients, is seeking candidates with relevant expertise to complement current Board members and support the company's strategy execution. The Board currently consists of five directors.
Board Chairperson Lynn Vos highlighted the company's progress under new CEO Steve Silvestro, focusing on building market share and driving profitable revenue growth. The company aims to address key pharma challenges including digital brand visibility, reducing script abandonment rates, enhancing point-of-care interoperability, and supporting specialty medications transition.
OptimizeRx (Nasdaq: OPRX) ha annunciato l'intenzione di nominare un nuovo direttore indipendente nel proprio Consiglio di Amministrazione nella seconda metà del 2025, proseguendo l'iniziativa di rinnovo del board. Questa nomina rappresenterà il terzo nuovo direttore dal 2020, dopo gli ingressi di Catherine Klema (2024) e Gregory D. Wasson (2020).
L'azienda, specializzata in soluzioni tecnologiche per la sanità che collegano le aziende delle scienze della vita con professionisti sanitari e pazienti, cerca candidati con competenze rilevanti per integrare i membri attuali del Consiglio e supportare l'esecuzione della strategia aziendale. Attualmente il Consiglio è composto da cinque membri.
La presidente del Consiglio, Lynn Vos, ha sottolineato i progressi dell’azienda sotto la guida del nuovo CEO Steve Silvestro, focalizzandosi sull’aumento della quota di mercato e sulla crescita redditizia dei ricavi. L’azienda mira a risolvere sfide chiave del settore farmaceutico, tra cui la visibilità digitale del brand, la riduzione dei tassi di abbandono delle prescrizioni, il miglioramento dell’interoperabilità al punto di cura e il supporto alla transizione verso i farmaci specializzati.
OptimizeRx (Nasdaq: OPRX) ha anunciado planes para nombrar un nuevo director independiente en su Junta Directiva durante la segunda mitad de 2025, continuando con su iniciativa de renovación del consejo. Este nombramiento será el tercer director nuevo desde 2020, tras las incorporaciones de Catherine Klema (2024) y Gregory D. Wasson (2020).
La empresa, especializada en soluciones tecnológicas para el sector salud que conectan a compañías de ciencias de la vida con profesionales sanitarios y pacientes, busca candidatos con experiencia relevante para complementar a los miembros actuales de la Junta y apoyar la ejecución de la estrategia de la compañía. Actualmente, la Junta está compuesta por cinco directores.
La presidenta de la Junta, Lynn Vos, destacó el progreso de la empresa bajo el nuevo CEO Steve Silvestro, enfocándose en aumentar la cuota de mercado y fomentar un crecimiento rentable de los ingresos. La compañía pretende abordar desafíos clave de la industria farmacéutica, incluyendo la visibilidad digital de la marca, la reducción de la tasa de abandono de recetas, la mejora de la interoperabilidad en el punto de atención y el apoyo en la transición hacia medicamentos especializados.
OptimizeRx (나스닥: OPRX)는 2025년 하반기에 이사회에 새로운 독립 이사를 임명할 계획을 발표하며 이사회 쇄신 이니셔티브를 이어가고 있습니다. 이번 임명은 2020년 이후 세 번째 신규 이사 선임으로, 이전에는 Catherine Klema(2024년)와 Gregory D. Wasson(2020년)이 임명되었습니다.
이 회사는 생명과학 기업과 의료 전문가 및 환자를 연결하는 헬스케어 기술 솔루션을 전문으로 하며, 현재 이사회 구성원을 보완하고 회사의 전략 실행을 지원할 관련 전문성을 갖춘 후보자를 찾고 있습니다. 현재 이사회는 다섯 명의 이사로 구성되어 있습니다.
이사회 의장 Lynn Vos는 신임 CEO Steve Silvestro 아래에서 시장 점유율 확대와 수익성 있는 매출 성장에 중점을 둔 회사의 진전을 강조했습니다. 회사는 디지털 브랜드 가시성, 처방 포기율 감소, 진료 현장 상호운용성 강화, 전문 의약품 전환 지원 등 주요 제약 과제를 해결하는 것을 목표로 하고 있습니다.
OptimizeRx (Nasdaq : OPRX) a annoncé son intention de nommer un nouveau directeur indépendant à son conseil d'administration au cours du second semestre 2025, poursuivant ainsi son initiative de renouvellement du conseil. Cette nomination sera le troisième nouveau directeur depuis 2020, après les arrivées de Catherine Klema (2024) et Gregory D. Wasson (2020).
L'entreprise, spécialisée dans les solutions technologiques de santé reliant les sociétés des sciences de la vie aux professionnels de santé et aux patients, recherche des candidats possédant une expertise pertinente pour compléter les membres actuels du conseil et soutenir l'exécution de la stratégie de l'entreprise. Le conseil compte actuellement cinq membres.
La présidente du conseil, Lynn Vos, a souligné les progrès réalisés sous la direction du nouveau CEO Steve Silvestro, en mettant l'accent sur l'augmentation de la part de marché et la croissance rentable du chiffre d'affaires. L'entreprise vise à relever des défis pharmaceutiques clés, notamment la visibilité numérique des marques, la réduction des abandons d’ordonnances, l’amélioration de l’interopérabilité au point de soin et le soutien à la transition vers les médicaments spécialisés.
OptimizeRx (Nasdaq: OPRX) hat Pläne bekannt gegeben, im zweiten Halbjahr 2025 einen neuen unabhängigen Direktor in seinen Vorstand zu berufen und setzt damit seine Initiative zur Erneuerung des Vorstands fort. Diese Ernennung wird der dritte neue Direktor seit 2020 sein, nach den Zugängen von Catherine Klema (2024) und Gregory D. Wasson (2020).
Das Unternehmen, das sich auf Gesundheitstechnologielösungen spezialisiert hat, die Life-Sciences-Unternehmen mit Gesundheitsfachkräften und Patienten verbinden, sucht Kandidaten mit relevanter Expertise, um die derzeitigen Vorstandsmitglieder zu ergänzen und die Umsetzung der Unternehmensstrategie zu unterstützen. Der Vorstand besteht derzeit aus fünf Mitgliedern.
Die Vorstandsvorsitzende Lynn Vos hob die Fortschritte des Unternehmens unter dem neuen CEO Steve Silvestro hervor, mit Fokus auf den Ausbau des Marktanteils und die Steigerung profitablen Umsatzwachstums. Das Unternehmen will zentrale Herausforderungen der Pharmaindustrie angehen, darunter digitale Markenpräsenz, Senkung der Abbruchraten bei Rezepten, Verbesserung der Interoperabilität am Point-of-Care und Unterstützung beim Übergang zu Spezialmedikamenten.
- Continued board refreshment shows commitment to corporate governance improvement
- Strategic focus on profitable revenue growth
- Expanding board expertise to support company's growth initiatives
- None.
WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx’s ongoing process to refresh and expand its board of directors (the “Board”), it intends to appoint a new independent director to its Board of Directors during the second half of this year.
With the appointment of a new independent director in 2025, OptimizeRx will have refreshed its Board, which is currently comprised of five directors, with three new directors since 2020, including Catherine Klema who was added in 2024 and Gregory D. Wasson who was added in 2020. As it begins its process of identifying a new independent director, the Board will be seeking an individual who has relevant expertise and experience that complements the current Board members and furthers the execution of the Company’s strategy and value creation plans.
“We remain very excited about the progress we are making in executing our strategy to build new market share and drive profitable revenue growth under the leadership of our new CEO Steve Silvestro as we leverage OptimizeRx’s industry leadership position in addressing pharma's most critical commercial challenges: improving brand visibility in an increasingly digital healthcare environment, reducing script abandonment rates, enhancing interoperability at the point of care, and supporting the shift toward complex specialty medications,” stated Lynn Vos, Chairperson of OptimizeRx's Board of Directors. “As we strategically plan for our next phase of growth, we are committed to recruiting new independent and highly-qualified directors who have perspectives, insights, experiences, and skills that expand the depth and breadth of our Board and contribute to our ability to execute our value creation plans and support key initiatives.”
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates", "believes", "estimates", "expects", "forecasts", "intends", "plans", "projects", "targets", "designed", "could", "may", "should", "will" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to OptimizeRx’s commitment to recruiting independent and highly-qualified directors who have perspectives, insights, experiences, and skills that expand the depth and breadth of the Board and the Company’s plans to build new market share and drive profitable revenue growth under the leadership of its new CEO Steve Silvestro and other statements relating to future performance, plans, and expectations. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to identify and appoint a new independent director, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Investor Relations Contact
Sandya von der Weid
LifeSci Advisors, LLC
svonderweid@lifesciadvisors.com
FAQ
How many new directors has OPRX appointed to its board since 2020?
What are the key strategic focuses of OptimizeRx under CEO Steve Silvestro?
When will OptimizeRx appoint its new independent director?
How many directors currently serve on OptimizeRx's board?
